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Introduction. 
Metabolic syndrome (MS) is one of the possible risk factors for coronary heart 
disease (CHD) [2,7]. Meanwhile, cardiovascular disease, and first and foremost, 
CHD, is one of the leading causes of death in developed countries of the world [1,8]. 
The prognosis for patients with coronary heart disease depends, predominantly, on 
the progression of coronary atherosclerosis (CA). Clinical significance of MS is 
determined by its important prognostic value in the development of cardiovascular 
diseases (CVD), and in particular, CHD, due to disturbance of the function of 
endothelial and smooth muscle cells of the vessels, local intravascular inflammation, 
increased platelets function and thrombosis [4,8]. The achievement of recent years is 
the concept as to the important role of chronic systemic inflammation (CSI) and 
insulin resistance (IR) in the pathogenesis of CA and CHD, which is especially 
relevant for MS patients [3, 8, 9]. 
CSI in CA is supported by induction of cytokine-associated pathways of 
intracellular signaling. The central component of CSI is the nuclear factor kappa B 
(NF-kB), the main activators of which are proinflammatory cytokines (CK), 
especially interleukin 1 (IL-1) and tumor necrosis factor α (TNFα) [3, 4]. The effector 
unit of CSI is the Th1 CK of the immune response type, involved in the formation 
and destabilization of the atheromatous plaque [5, 9]. 
Due to the structural and functional remodeling, activation of neuro-humoral 
systems and reactions involving inflammatory molecules in patients with CHD, the 
systolic function of the left ventricle (LV) is impaired. The biomechanical 
reorganization of the heart causes changes in the expression of genes that mediate 
CSI, apoptotic reactions, etc. [6]. 
The aim of our research was to study the relationship between the level of CSI 
and impaired central hemodynamics in patients with CHD with metabolic syndrome. 
Materials and methods. 
We examined 115 patients with coronary heart disease against the background 
of MS, who met the main criteria of IDF and WHO: 64 men and 51 women aged 
57+8.3 years) and 30 apparently healthy individuals (the control group). 
The criteria for inclusion in the study were the age of men and women of 40-75 
years, the presence of coronary heart disease: exertional angina, FC II, in the absence 
of destabilization of the course for at least two months with metabolic syndrome, 
informed consent of the patient to participate in the study. The exclusion criteria were 
the presence of chronic heart failure above stage I, high blood pressure, 
complications of cardiac rhythm and conduction, rheumatism, cancer, anemia, renal 
and hepatic insufficiency. 
To achieve the aim of the research, patients were examined in terms of blood 
levels of IL-1β and TNFα, fibrinogen (FG) of plasma and underwent 
echocardiography (echo) [7]. The global contractile ability of the LV was estimated 
by the shock volume (SV), the ejection fraction (EF) and the velocity of blood flow 
(v) in the outer tract (OT) of the LV. The diastolic function of the LV was 
investigated by recording the transmitral blood flow rates by the ratio of the rates of 
early (E) and late (A) diastolic LV filling (E / A), by the time of retarding of the early 
diastolic filling of the LV (DT) and the time of isovolumetric relaxation (IVRT) [7]. 
Results. In patients with CHD with MS, an increase in blood concentrations of 
pro-inflammatory CKs was found: the TNFα level was 8.38+2.15 pg / ml, and the 
level of IL-1β was 9.29+2.80 pg / ml. In 37.4% of patients with CHD, high levels of 
FG in the blood plasma were observed. 
In patients with CHD with MS, EF of the LV, SV and v in OT of the LV were 
significantly lower in comparison with the group of apparently healthy persons (p 
<0.05). The ratio of transmitral blood flow phases in patients with coronary heart 
disease was disturbed – E / A <1, DT was increased (p <0.05), IVRT was delayed (p 
<0.05). 
The study of the ratio of indicators of central hemodynamics and CSI markers 
revealed the inverse correlation between EF of the LV and TNFα (r = -0.340, p 
<0.05), EF of the LV and FG (r = -0.369, p <0.01), E / A and IL-1β (r = 0.333, p 
<0.05). 
Conclusion. The obtained results demonstrate the negative effect of CSI on the 
systolic and diastolic function of the LV in patients with CHD with MS. 
Prospects for further research. Further study of the levels of pro-
inflammatory CKs and other markers of inflammation in patients with CA and CHD 
with MS can be the basis for constructing a diagnostic algorithm to determine the 
predictors of destabilization of the course and progression of this pathology for the 
development of optimal pathogenetically substantiated therapies. 
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